Title: Inflammatory and Nutritional Markers Predict Response and Prognosis of Patients with
Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy
Version: 0 Date: 19 Mar 2025
Reviewer's report:
In this study, the authors analyzed 134 gastric cancer patients, who received radical resection
after neoadjuvant immunochemotherapy. They found that CONUT score and NRS2002 score
are independent factors of tumor regression in LAGC patients.
Also, the authors newly constructed CONUT-NRS2002 combined score for a new predictive
indicator, and they found this new indicator had a good potential in predicting tumor regression
and prognosis of LAGC patients after neoadjuvant immunochemotherapy.
Please clarify these points described below.
The authors referred ref.15 as the explanation of NRS2002, however the reference did not
directly indicate about NRS2002.
Please choose another reference for the details of NRS2002.
As the authors showed, the new CONUT-NRS2002 combined score related with the prognosis
after neoadjuvant immunochemotherapy. The mechanism the authors mentioned in discussion
is reasonable about cancer-bearing patients. However about immunochemotherapy, this is not
sufficient for explanation of this good correlation between nutrition scores and prognosis
after immunochemotherapy. I think for immunochemotherapy, PD-L1 may be a more suitable
predictor for the prognosis after immunochemotherapy. Did you measure this indicator? If so,
please discuss about the relationship between PD-L1 and your new combined score.
Title: Inflammatory and Nutritional Markers Predict Response and Prognosis of Patients with
Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy
Version: 0 Date: 19 Mar 2025
Reviewer's report:
In this study, the authors analyzed 134 gastric cancer patients, who received radical resection
after neoadjuvant immunochemotherapy. They found that CONUT score and NRS2002 score
are independent factors of tumor regression in LAGC patients.
Also, the authors newly constructed CONUT-NRS2002 combined score for a new predictive
indicator, and they found this new indicator had a good potential in predicting tumor regression
and prognosis of LAGC patients after neoadjuvant immunochemotherapy.
Please clarify these points described below.
The authors referred ref.15 as the explanation of NRS2002, however the reference did not
directly indicate about NRS2002.
Please choose another reference for the details of NRS2002.
As the authors showed, the new CONUT-NRS2002 combined score related with the prognosis
after neoadjuvant immunochemotherapy. The mechanism the authors mentioned in discussion
is reasonable about cancer-bearing patients. However about immunochemotherapy, this is not
sufficient for explanation of this good correlation between nutrition scores and prognosis
after immunochemotherapy. I think for immunochemotherapy, PD-L1 may be a more suitable
predictor for the prognosis after immunochemotherapy. Did you measure this indicator? If so,
please discuss about the relationship between PD-L1 and your new combined score.
Please review this paper.
user
Title: Inflammatory and Nutritional Markers Predict Response and Prognosis of Patients with
Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy
Version: 0 Date: 19 Mar 2025
Reviewer's report:
In this study, the authors analyzed 134 gastric cancer patients, who received radical resection
after neoadjuvant immunochemotherapy. They found that CONUT score and NRS2002 score
are independent factors of tumor regression in LAGC patients.
Also, the authors newly constructed CONUT-NRS2002 combined score for a new predictive
indicator, and they found this new indicator had a good potential in predicting tumor regression
and prognosis of LAGC patients after neoadjuvant immunochemotherapy.
Please clarify these points described below.
The authors referred ref.15 as the explanation of NRS2002, however the reference did not
directly indicate about NRS2002.
Please choose another reference for the details of NRS2002.
As the authors showed, the new CONUT-NRS2002 combined score related with the prognosis
after neoadjuvant immunochemotherapy. The mechanism the authors mentioned in discussion
is reasonable about cancer-bearing patients. However about immunochemotherapy, this is not
sufficient for explanation of this good correlation between nutrition scores and prognosis
after immunochemotherapy. I think for immunochemotherapy, PD-L1 may be a more suitable
predictor for the prognosis after immunochemotherapy. Did you measure this indicator? If so,
please discuss about the relationship between PD-L1 and your new combined score.
assistant